Achieve Life Sciences ACHV Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -257.7%— | —— | —— | -233%-132pp | |
| Return on assets | -135.9%+1.4pp | -137.3%-16.5pp | -120.9%-11.5pp | -109.3%-33.8pp | |
| Return on invested capital | -852.7%— | —— | —— | —— | |
| Liquidity | |||||
| Current ratio | 4.4×-1.1× | 5.5×+4.6× | 0.8×-0.4× | 1.3×-8.5× | |
| Quick ratio | 4.4×-1.1× | 5.5×+4.6× | 0.8×-0.4× | 1.3×-8.5× | |
| Cash ratio | 2.3×+0.4× | 1.9×+1.2× | 0.7×-0.4× | 1.1×-8.3× | |
| Leverage | |||||
| Debt-to-equity | 0.2×+0.2× | 0×— | —— | 2×+1.9× | |
| Debt-to-assets | 0.1×+0.1× | 0×-0.9× | 0.9×+0.3× | 0.5×+0.5× | |
| Interest coverage | -65.7×-48.5× | -17.3×-7.8× | -9.5×+13.2× | -22.7×— | |
| Per Share | |||||
| Book value per share | $0.49-24.2% | $0.65+993% | -$0.07-109% | $0.78-77.3% | |
| Valuation | |||||
| Market capitalization | $585.16M+404% | $121.05M+38.8% | $87.2M+98.9% | $43.85M-40.4% | |
| Enterprise value | $562.71M+439% | $108.42M+22.7% | $88.39M+151% | $35.27M+15.3% | |
| Price / book | 54.8×+43.5× | 5.8×— | —— | 5.3×+2.7× | |
| Free cash flow yield | -18.7%— | —— | —— | —— | |
| Earnings yield | -8.9%+30.8pp | -32.9%+1.3pp | -34.2%+62.4pp | -96.6%-51.5pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Achieve Life Sciences's ratios come from?
- Every ratio is computed from Achieve Life Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.